NCT02867852View on ClinicalTrials.gov

Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

November 30, 2019

Study Completion Date

May 31, 2020

Conditions
Salivary Glands Tumors
Interventions
DRUG

Abiraterone acetate

Abiraterone acetate is a prodrug of abiraterone, an irreversible inhibitor of 17α hydroxylase/C17, 20-lyase (cytochrome P450c17 \[CYP17\]), a key enzyme required for testosterone synthesis. This enzyme is found in the testes, adrenals, prostate tumors

Trial Locations (1)

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

All Listed Sponsors
lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER

NCT02867852 - Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland Cancers | Biotech Hunter | Biotech Hunter